Psoriasis is a common chronic inflammatory skin disease but psoriasis patients with renal impairment undergoing dialysis are not frequently seen. Furthermore, the published work contains little information on the treatment with biologic drugs of patients with end-stage renal disease. We describe a 57-year-old man with refractory plaque-type psoriasis and end-stage renal disease due to polycystic kidney disease undergoing hemodialysis. He had tried topical medications and ultraviolet therapy for many years and was then treated with ustekinumab (an interleukin-12 and interleukin-23 blocker), which resulted in good clinical response along with stable renal function. After a few years of therapy, no side-effects have been observed. Our experience with this patient expands the spectrum of ustekinumab to include psoriasis patients with renal failure undergoing hemodialysis.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1346-8138.12989 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and validation of an algorithm for identifying patients undergoing dialysis from patients with advanced chronic kidney disease.
Clin Exp Nephrol
January 2025
Department of Nephrology, Nagoya University Graduate School of Medicine, 65 Tsurumai-cho, Showa-ku, Nagoya, Aichi, 464-8550, Japan.
Background: Identifying patients on dialysis among those with an estimated glomerular filtration rate (eGFR) < 15 mL/min/1.73 m remains challenging. To facilitate clinical research in advanced chronic kidney disease (CKD) using electronic health records, we aimed to develop algorithms to identify dialysis patients using laboratory data obtained in routine practice.
View Article and Find Full Text PDFA novel LC-MS/MS assay for low concentrations of creatinine in sweat and saliva to validate biosensors for continuous monitoring of renal function.
J Chromatogr B Analyt Technol Biomed Life Sci
December 2024
Clinical Laboratory, Catharina Hospital Eindhoven, Eindhoven 5623 EJ, The Netherlands; Department of Biomedical Engineering, Chemical Biology, Eindhoven University of Technology, Groene Loper 3, Eindhoven 5612 AE, The Netherlands.
Monitoring of kidney function traditionally relies on plasma creatinine concentrations, necessitating invasive blood draws. Non-invasively obtainable biofluids, such as sweat and saliva, present a patient-friendly alternative with potential for continuous monitoring. This study focusses on developing and validating a novel Liquid Chromatography- tandem Mass Spectrometry (LC-MS/MS) assay as a reference test for measuring low creatinine concentrations in sweat and saliva.
View Article and Find Full Text PDFThe steady-state pharmacokinetics of fixed-dose combination dolutegravir+rilpivirine in hemodialysis.
AIDS
November 2024
Division of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, IN, USA.
Objective: Fixed dose combination (FDC) dolutegravir (DTG) plus rilpivirine (RPV) is an approved antiretroviral treatment regimen for people with HIV. The steady-state pharmacokinetics (PK) of FDC DTG+RPV in hemodialysis (HD) has not been previously studied.
Design: We performed a single-center, prospective evaluation of the steady-state PK of FDC DTG +RPV in 4 adults without HIV either requiring HD and in 4 matched participants with normal renal function.
Terminological subset of ICNP® for people with chronic kidney disease on hemodialysis.
Rev Esc Enferm USP
January 2025
Universidade do Estado do Rio de Janeiro, Faculdade de Enfermagem, Departamento de Fundamentos de Enfermagem, Rio de Janeiro, RJ, Brazil.
Objectives: To construct and validate a terminological subset of the International Classification of Nursing Practice (ICNP®) for people with chronic kidney disease on hemodialysis.
Method: Methodological study developed in accordance with the recommendations of the International Council of Nurses (ICN) and the Brazilian method, in the following stages: construction of ND/NO and NI statements of the ICNP® for nursing practice for people with chronic kidney disease on hemodialysis, based on previously constructed specialized terminology and in accordance with Wanda Horta's Basic Human Needs Theory; and content validation of the statements by focus groups with specialist nurses. The Content Validity Index was used and statements ≥ 0.
Effect of Antithrombin Leakage From Hemodialysis Therapy on Antithrombin Hemodynamics.
Cureus
December 2024
Clinical Laboratory Science, Graduate School of Medical Science, Kanazawa University, Kanazawa, JPN.
Introduction Hemodialysis (HD) therapy is a crucial treatment for patients with renal failure but can impact the hemodynamics of antithrombin (AT), a protein essential for regulating hemostasis and preventing thrombosis. Reduced AT activity can lead to thrombus formation at unusual sites and increase the risk of recurrent venous thromboembolism. The loss of AT during HD or hemodiafiltration (HDF) through leakage or adsorption onto dialysis membranes has not been fully investigated, and its effects on AT hemodynamics remain unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!